Skip to main content
. Author manuscript; available in PMC: 2006 Sep 28.
Published in final edited form as: Cardiovasc Res. 2004 Feb 1;61(2):256–267. doi: 10.1016/j.cardiores.2003.11.007

Fig. 4.

Fig. 4

Antiarrhythmic effects of mexiletine in TGM(NS31)L12 mice. The incidence of cardiac events ( y-axis) is plotted for each hour over a 24-h period. The data are a culmination of all events for 30 (A) and 14 (B) consecutive days, the latter of which received mexiletine administrations (25 mg/kg, i.p.) at 1400 and 1800 h (arrows 1 and 2, respectively). Cardiac arrhythmias were fully suppressed immediately following and up to 6 h posttreatment with mexiletine. Since no lethal arrhythmias were detected in TGM(NS31)L3, mexiletine treatment studies were not performed.